title: Efficacy of 3,4,3-LIHOPO for reducing the retention of 238Pu in rat after inhalation of the tributyl phosphate complex.
abstract: The efficacy of 3,4,3-LIHOPO, a siderophore analogue, has been tested for removing 238Pu from rat after inhalation of plutonium as the tri-N-butylphosphate (TBP) complex. The amounts of Pu retained in the lung of untreated rat, 7 days after exposure ranged from 0.86 to 37 kBq. The results have been compared with DTPA, the current therapy of choice for man. The ligand 3,4,3-LIHOPO was more effective than DTPA for removing Pu from the body when repeated treatment began 1 h after inhalation. This observation was independent of the mass of Pu deposited in the lungs. The efficacy of 3,4,3-LIHOPO was mainly due to the decrease of Pu retention in lung, 1.5 times less than after DTPA administration; in liver and skeleton, retention was about four times less. Seven days after internal contamination, < 10% of the activity was found in organs other than lung when rat was treated with 3,4,3-LIHOPO. As this ligand showed an apparent lack of irreversible toxicity, it is likely to be of interest in the development of new decorporation treatments after inhalation of Pu as a TBP complex.
authors.affiliation: CEA, DSV/DPTE/LRT, Bruyères le Châtel, France.
authors.forename: J L
authors.initials: JL
authors.lastname: Poncy
authors.forename: G
authors.initials: G
authors.lastname: Rateau
authors.forename: R
authors.initials: R
authors.lastname: Burgada
authors.forename: T
authors.initials: T
authors.lastname: Bailly
authors.forename: Y
authors.initials: Y
authors.lastname: Leroux
authors.forename: K N
authors.initials: KN
authors.lastname: Raymond
authors.forename: P W
authors.initials: PW
authors.lastname: Durbin
authors.forename: R
authors.initials: R
authors.lastname: Masse
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D001372:Aza Compounds / Q000627:therapeutic use*; D003666:Decontamination; D008168:Lung / Q000378:metabolism; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010755:Organophosphates / Q000008:administration & dosage* / Q000493:pharmacokinetics; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004369:Pentetic Acid / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D001372:Aza Compounds; D009942:Organometallic Compounds; D010755:Organophosphates; D009943:Organophosphorus Compounds; D011728:Pyridones; C038503:plutonium tri-n-butylphosphate complex; C076998:N,N',N'',N'''-tetra(1,2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1,5,10,14-tetraazatetradecane; D004369:Pentetic Acid